Stability of blood phenylalanine levels and IQ in children with phenylketonuria (Q43994471)

28 November 2017

Stability of blood phenylalanine levels and IQ in children with phenylketonuria (English)

1 reference

28 November 2017

1 reference

Vera Anastasoaie

1

1 reference

28 November 2017

Laura Kurzius

series ordinal

2

1 reference

28 November 2017

Peter Forbes

series ordinal

3

1 reference

28 November 2017

Susan Waisbren

series ordinal

4

1 reference

28 November 2017

13 August 2008

1 reference

Molecular Genetics and Metabolism

28 November 2017

1 reference

28 November 2017

95

1 reference

28 November 2017

1-2

1 reference

28 November 2017

17-20

1 reference

The hyperphenylalaninemias of man and mouse

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Correction of phenylketonuria after liver transplantation in a child with cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Situational analysis of dietary challenges of the treatment regimen for children and adolescents with phenylketonuria and their primary caregivers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Influence of phenylalanine intake on phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

A novel approach for enzyme replacement therapy. The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.06.014

10.1016/J.YMGME.2008.06.014

7 January 2021

Identifiers

DOI

1 reference

28 November 2017

1 reference